$ cat ./records/committed-2-1-billion-to-covid-19-vaccine-development-and-equitab-2020.txt
Committed $2.1 billion to COVID-19 vaccine development and equitable access
[RECORD.TXT] · cat --full
At the onset of the COVID-19 pandemic, the Gates Foundation pledged $250 million in emergency funding, later expanding total commitments to over $2.1 billion. Gates co-led the COVAX facility alongside Gavi and CEPI to pool funding for vaccine development and ensure doses reached low-income countries. He was among the first prominent voices to argue that vaccine access must be treated as a global public good, drawing significant international attention to the risk of wealthy nations monopolizing early vaccine supply.
Source: https://www.gatesfoundation.org/ideas/articles/coronavirus-covid19-gates-foundation-response
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Invests in Form Energy's iron-air battery for 100-hour grid storage
Next →
Study Ranks Bill Gates Among the Top Celebrity Carbon Emitters From Private Jets
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.